Tandem Health raises 100 million dollars to build an AI clinic operating system for Europe

Tandem Health, a Stockholm based health technology company that builds an artificial intelligence medical assistant for European clinics, announced a 100 million dollar Series B round on September 14, 2026. The round, worth 86.5 million euros, was led by the Scaleup Europe Fund, which is managed by the Swedish investment firm EQT, and it lifts the company's total funding to 160 million dollars, or 138.38 million euros.

The announcement lands at a moment when European health systems are under severe strain. Tech Funding News reported on September 14 that the World Health Organization expects Europe to face a shortfall of 1.6 million health and social care workers this year, a figure that could climb to 4 million by 2030. The same outlet noted that Eurostat forecasts that by 2050 there will be fewer than two working age adults for every retiree, as the number of Europeans over the age of 65 approaches 130 million.

Tandem sells three modules: an AI scribe that documents consultations, a coding assistant and a clinical decision support tool. Each one is independently certified as a Class IIa medical device under the EU Medical Device Regulation, a distinction the company says no competitor in the category can match. The business also holds ISO 27001, ISO 13485 and ISO 42001 certifications, alongside C5 in Germany, ENS High in Spain and HDS in France.

The company was founded in 2023 by chief executive Lukas Saari, chief technology officer Oliver Åstrand and chief commercial officer Oscar Boldt-Christmas. Saari previously led McKinsey's Nordic healthcare analytics team and worked on machine learning at Spotify. Åstrand built AI products at Google X, Uber, Depict and Mavenoid. Boldt-Christmas spent 20 years as a senior partner at McKinsey, where he headed its European healthcare practice. In June 2025 the company announced a 42.6 million euro Series A led by Kinnevik.

Key Facts

EU-Startups reported on September 14 that the Series B was led by the EQT managed Scaleup Europe Fund, with continued support from existing investors Kinnevik, Northzone, Amino Collective and Visionaries. Demócrata reported the same day that new backers T.Capital, the investment vehicle of Deutsche Telekom, and Norrsken Ventures also joined the round. That combination gives Tandem both deep Nordic venture backing and a strategic link to a major European telecommunications group.

The cheque is not the fund's first. Tech Funding News reported on September 14 that the 5 billion euro Scaleup Europe Fund was established to help ensure that leading European technology companies remain in the region, and that Tandem is only its second investment, following a 400 million dollar round for Lovable. It is the fund's first investment in the healthcare sector, and EQT managing director Nils Petter Nygaard said Tandem could become the foundational AI layer for European healthcare.

Tandem's product is already broadly deployed. The SaaS News reported on September 14 that the platform is used by 10,000 care organisations across 14 European markets. Named customers include Ramsay Santé, Humanitas and the NHS, and in Spain Grupo Recoletas Salud, Hospiten and ITA Salud Mental.

The company cites peer reviewed research published in JMIR showing that clinicians using Tandem recorded a 29 percent reduction in time spent on administrative work, a 30 percent improvement in job satisfaction and a 30 percent reduction in administrative stress. Those numbers matter because burnout, rather than technology scepticism, is the main reason clinicians leave.

Tandem says it will use the capital to expand a team of more than 75 in house clinicians and to evolve the product from an AI medical assistant into an AI native clinic operating system. That system, in the company's description, would also manage patient flows and integrate agents able to resolve additional clinical tasks.

Analysis

The bigger picture here is that European health technology has spent a decade producing narrow point solutions, and the capital is now consolidating around platforms that can carry regulatory approval across borders. Tandem is making a deliberate bet that documentation is only the entry point, and that whoever owns the clinical workflow will own the category.

The competitive map explains the urgency. Paris based Nabla and Australia based Heidi Health operate in adjacent territory, while Abridge has raised around 780 million dollars at a 5.3 billion dollar valuation. Abridge, however, was built for United States regulatory and reimbursement conditions, which makes it a poor fit for the fragmented European patchwork of national health systems, languages and data protection regimes. Tandem's certifications, C5 in Germany, ENS High in Spain and HDS in France, are the practical machinery that lets a single product cross those borders.

Saari framed the opportunity bluntly. Tech Funding News reported on September 14 that he said Europe's health systems are under real strain and that AI presents a real solution. That is a founder's line, but the structural numbers behind it are not promotional. A projected shortfall of 1.6 million health and social care workers this year, and a potential 4 million by 2030, is a gap that hiring alone cannot close.

The market forecast adds the commercial logic. The clinical documentation segment of the generative AI market is projected to grow from 1.05 billion dollars in 2026 to 10.5 billion dollars by 2034. If Tandem converts its installed base of 10,000 care organisations from a scribe into an operating system, it multiplies revenue per account without needing to win a single new logo. That is the difference between a 160 million dollar funded startup and a company that justifies a much larger valuation later.

Why It Matters

For clinicians, the significance is measured in hours. A 29 percent reduction in administrative time is not a marginal gain; in a system where the World Health Organization sees a 1.6 million worker deficit, recovered minutes are the only capacity that can be created quickly without training new staff. The 30 percent improvement in job satisfaction and the 30 percent reduction in administrative stress point at retention, which is where European systems bleed most.

For Europe, the round is a test of whether the continent can keep its most promising health technology companies at home. The Scaleup Europe Fund was created precisely because too many European founders have relocated to the United States in search of later stage capital and a single large market. Tandem is the fund's first healthcare investment and only its second overall, which makes it a signal as much as a transaction. If it works, more European capital will follow into clinical AI.

For patients, the stakes are slower and more diffuse. An operating system that coordinates patient flows, rather than a tool that merely writes notes, touches waiting lists, referrals and follow up. Hospitals in 14 markets are already running the underlying technology, so the change will arrive inside existing systems rather than through new procurement cycles.

Next Up

The immediate work is hiring and product. Tandem intends to expand its 75 plus in house clinicians and to ship the clinic operating system features, including patient flow management and task resolving agents, while consolidating its presence in its 14 active European markets. Registration and compliance work in additional jurisdictions is likely to run alongside that roadmap.

The wider question is whether the Scaleup Europe Fund's second bet sets a pattern. With 5 billion euros to deploy and a mandate to keep European technology champions on the continent, its next healthcare cheques will be read as a verdict on the sector. Tandem's Series B gives the fund its first data point, and the market will judge it by how far the company moves beyond the medical assistant it sells today.